DekaBank Deutsche Girozentrale Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

DekaBank Deutsche Girozentrale grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 183,376 shares of the biopharmaceutical company's stock after purchasing an additional 60,000 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.16% of Catalyst Pharmaceuticals worth $3,532,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company's stock worth $119,694,000 after acquiring an additional 73,930 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $426,000. State of Alaska Department of Revenue boosted its holdings in shares of Catalyst Pharmaceuticals by 10.4% in the 1st quarter. State of Alaska Department of Revenue now owns 68,038 shares of the biopharmaceutical company's stock valued at $1,084,000 after buying an additional 6,386 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of Catalyst Pharmaceuticals by 10.5% in the 1st quarter. Maryland State Retirement & Pension System now owns 40,262 shares of the biopharmaceutical company's stock valued at $635,000 after buying an additional 3,840 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 1st quarter worth approximately $360,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Finally, Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average target price of $29.50.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Carmen Jeffrey Del sold 36,058 shares of the business's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now directly owns 12,369 shares in the company, valued at $227,836.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director David S. Tierney sold 15,000 shares of the business's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company's stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 201,058 shares of company stock worth $4,018,188. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Trading Up 0.4 %

NASDAQ CPRX traded up $0.09 on Friday, hitting $21.89. 999,298 shares of the company's stock traded hands, compared to its average volume of 1,188,807. The firm's 50-day moving average price is $20.47 and its two-hundred day moving average price is $17.77. The firm has a market capitalization of $2.60 billion, a PE ratio of 40.87, a P/E/G ratio of 3.44 and a beta of 0.76. Catalyst Pharmaceuticals, Inc. has a 1-year low of $12.27 and a 1-year high of $22.27.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.39 by $0.13. The company had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. On average, research analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.